We show that most combinatorial dose regimens achievable in the clinic are effective for treating BRAF mutant melanoma thanks to the higher single-agent potency and drug additivity, whereas NRAS mutant melanoma requires more precise dosing to harness drug synergy, posing practical implementation challenges due to interpatient pharmacokinetic variability. The gene discussed is NRAS; the disease is melanoma.